Comparing biomarkers as principal surrogate endpoints

DOI10.1111/J.1541-0420.2011.01603.XzbMATH Open1274.62793OpenAlexW2002963026WikidataQ28740935 ScholiaQ28740935MaRDI QIDQ2893405FDOQ2893405

Authors: Peter B. Gilbert, Ying Huang 

Publication date: 20 June 2012

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc3163011

Recommendations

• Evaluating Candidate Principal Surrogate Endpoints
• Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials
• A multiple imputation approach for the evaluation of surrogate markers in the principal stratification causal inference framework
• The Evaluation of Multiple Surrogate Endpoints
• On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm

zbMATH Keywords

semiparametricprincipal stratificationpredictiveness curveestimated likelihoodsurrogate markertotal gain

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Principal stratification in causal inference
• Weighted Likelihood for Semiparametric Models and Two‐phase Stratified Samples, with Application to Cox Regression
• Evaluating Candidate Principal Surrogate Endpoints
• Semiparametric Estimation of Regression Quantiles with Application to Standardizing Weight for Height and Age in US Children
• Related Causal Frameworks for Surrogate Outcomes
• The binary regression quantile plot: Assessing the importance of predictors in binary regression visually
• Evaluating the Predictiveness of a Continuous Marker
• A Bayesian approach to surrogacy assessment using principal stratification in clinical trials
• The evaluation of surrogate endpoints.
• The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
• The validation of surrogate endpoints in meta-analyses of randomized experiments
• Augmented Designs to Assess Immune Response in Vaccine Trials
• Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials

Cited In (20)

• Design and estimation for evaluating principal surrogate markers in vaccine trials
• Quantifying the feasibility of shortening clinical trial duration using surrogate markers
• Robust Approach to Combining Multiple Markers to Improve Surrogacy
• Surrogate measures and consistent surrogates
• Identification of the optimal treatment regimen in the presence of missing covariates
• Semiparametric pseudo-score and pseudo-likelihood for evaluating correlate of protection in vaccine trials
• Simultaneous inference of treatment effect modification by intermediate response endpoint principal strata with application to vaccine trials
• Evaluating Candidate Principal Surrogate Endpoints
• Evaluating multiple surrogate markers with censored data
• Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials
• Testing for Heterogeneity in the Utility of a Surrogate Marker
• Estimation of the proportion of treatment effect explained by a high-dimensional surrogate
• A multiple imputation approach for the evaluation of surrogate markers in the principal stratification causal inference framework
• Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption
• A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint
• Identification of causal effects within principal strata using auxiliary variables
• Assessing the value of a censored surrogate outcome
• Comparing biomarkers as trial level general surrogates
• Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling
• A unified evaluation of differential vaccine efficacy

This page was built for publication: Comparing biomarkers as principal surrogate endpoints

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2893405)